T-cell therapies for T-cell lymphoma

Abstract

T-cell lymphomas represent a subpopulation of non-Hodgkin lymphomas with poor outcomes when treated with conventional chemotherapy. A variety of novel agents have been introduced as new treatment strategies either as first-line treatment or in conjunction with chemotherapy. Immunotherapy has been demonstrated to be a promising area for new therapeutics, including monoclonal antibodies and adoptive cellular therapeutics. T-cell therapeutics have been shown to have significant success in the treatment of B-cell malignancies and are rapidly expanding as potential treatment options for other cancers including T-cell lymphomas. Although treating T-cell lymphomas with T-cell therapeutics has unique challenges, multiple targets are currently being studied both preclinically and in clinical trials.

Keywords: EBV-associated lymphoma; T-cell receptor; adoptive cellular therapies; anaplastic large cell lymphoma; chimeric antigen receptor T cells; immunotherapy; monoclonal antibody; non-Hodgkin lymphoma; peripheral T-cell lymphoma; tumor-associated antigen.